Rady Mohamed Y, Johnson Daniel J, Patel Bhavesh, Larson Joel, Helmers Richard
Department of Critical Care Medicine, Mayo Clinic College of Medicine, Mayo Clinic Hospital, Mayo Clinic, Phoenix, Arizona, USA.
Crit Care. 2006;10(4):R101. doi: 10.1186/cc4971.
Use of corticosteroids for adrenal supplementation and attenuation of the inflammatory and immune response is widespread in acute critical illness. The study hypothesis was that exposure to corticosteroids influences the mortality and morbidity in acute critical illness.
This case-control retrospective study was performed in a single multidisciplinary intensive care unit at a tertiary care institution and consisted of 10,285 critically ill patients admitted between 1 January 1999 and 31 December 2004. Demographics, comorbidities, acute illness characteristics including severity measured by Sequential Organ Failure Assessment, concurrent medications, therapeutic interventions and incidence of infections were obtained from electronic medical records, were examined with multiple regression analysis and were adjusted for propensity of corticosteroid exposure. The primary outcome was hospital death, and the secondary outcome was transfer to a care facility at hospital discharge.
Corticosteroid exposure in 2,632 (26%) patients was characterized by younger age, more females, higher Charlson comorbidity and maximal daily Sequential Organ Failure Assessment scores compared with control patients. Corticosteroids potentiated metabolic and neuromuscular sequels of critical illness with increased requirements for diuretics, insulin, protracted weaning from mechanical ventilation, need for tracheostomy and discharge to a care facility. Early exposure to corticosteroids predisposed to recurrent and late onset of polymicrobial and fungal hospital-acquired infections. Corticosteroids increased the risk for death or disability after adjustments for comorbidities and acute illness characteristics.
Corticosteroids increased the risk for death or disability in critical illness. Hospital-acquired infections and metabolic and neuromuscular sequels of critical illness were exacerbated by corticosteroids. Careful appraisal of the indications for use of corticosteroids is necessary to balance the benefits and risks from exposure in acute critical illness.
在急性危重病中,使用皮质类固醇进行肾上腺补充以及减轻炎症和免疫反应的情况很普遍。研究假设是,接触皮质类固醇会影响急性危重病的死亡率和发病率。
本病例对照回顾性研究在一家三级医疗机构的单一多学科重症监护病房进行,纳入了1999年1月1日至2004年12月31日期间收治的10285例危重病患者。从电子病历中获取人口统计学资料、合并症、急性疾病特征(包括用序贯器官衰竭评估法测量的严重程度)、同时使用的药物、治疗干预措施以及感染发生率,进行多元回归分析,并对皮质类固醇暴露倾向进行调整。主要结局是医院死亡,次要结局是出院时转至护理机构。
2632例(26%)患者有皮质类固醇暴露史,与对照患者相比,其特点为年龄较轻、女性较多、Charlson合并症指数较高以及序贯器官衰竭评估每日最高分较高。皮质类固醇使危重病的代谢和神经肌肉后遗症加重,利尿剂、胰岛素需求增加,机械通气脱机时间延长,需要气管切开术,且出院后转至护理机构。早期接触皮质类固醇易导致多种微生物和真菌医院获得性感染的复发和迟发。在对合并症和急性疾病特征进行调整后,皮质类固醇增加了死亡或残疾风险。
皮质类固醇增加了危重病患者的死亡或残疾风险。皮质类固醇加剧了医院获得性感染以及危重病的代谢和神经肌肉后遗症。在急性危重病中,必须仔细评估皮质类固醇的使用指征,以平衡暴露的益处和风险。